With the adoption of Regulation (EC) No 141/2000 of the European Commission, conditions were created for the development of orphan drugs and, as a result, the Committee for Orphan Medicinal Products has evaluated, since its foundation in 2000, about 2500 requests for naming medical products as orphan drugs.

Article by Bruno Sepodes
in Public, August 11, 2016

Read full article here